Sustained latanoprost release from PEGylated solid lipid nanoparticle-laden soft contact lens to treat glaucoma

Dang, Hui; Dong, Chunyun; Zhang, Li

doi:10.1080/10837450.2021.1999471

Cited by 39 publications

(19 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[57][58][59] The microemulsion-laden contact lens (Bri-ME) showed a statistically insignificant (p = 0.09) increase in the lysozyme adherence compared to the blank contact lens, which was expected as surfactant prevent protein adherence. 60,61 The lysozyme adherence value of the silica nanoparticlesladen contact lens (11.7 ± 1.5 µg/lens) was close (p = 0.58) to that of the control blank contact lens, due to balance of surfactants and hydrophobic silica nanoparticles. Thus, the issue of protein adherence due to the hydrophobic nature of brimonidine was addressed by encapsulation in silica nanoparticles.…”

Section: Lysozyme Adherence Studiesmentioning

confidence: 67%

In vitro and in vivo evaluation of brimonidine loaded silica nanoparticles-laden silicone contact lenses to manage glaucoma

2022

J Biomater Appl

View full text Add to dashboard Cite

Glaucoma is treated by frequent instillation of 0.2% w/v brimonidine tartrate eye drop solution, which showed poor ocular bioavailability of 1–3%. Medicated contact lenses can be used to improve the ocular drug bioavailability. However, drug loading in the contact lens matrix showed high burst release and changes the optophysical properties of the contact lens material. In this paper, a novel brimonidine loaded silica nanoparticles-laden silicone contact lenses (Bri-Si) were designed to achieve controlled drug delivery without altering the optophysical properties of the contact lens. Silica nanoparticles were prepared by polymerizing octadecyltrimethoxysilane (OTMS) molecules at the oil/water interface of microemulsion. Traditional soaking method (Bri-SM), direct brimonidine-loading method (Bri-DL) and microemulsion-laden contact lens (Bri-ME) were developed for comparison. The Bri-Si lens showed improved swelling, transmittance, oxygen permeability and lysozyme adherence compared to Bri-SM, Bri-DL and Bri-ME lenses. The Bri-DL lens showed high brimonidine leaching during extraction and sterilization steps, with low cumulative drug release. While, Bri-Si lens show controlled brimonidine release for 144 h. In a rabbit tear fluid model, the Bri-Si lens showed high brimonidine concentration for 96 h compared to Bri-ME lens and eye drop therapy. Based on histopathological studies of cornea, the Bri-Si lens was found to be safe for human applications. The data demonstrated the novel application of silica nanoparticles to control brimonidine release from the contact lens without altering the optophysical properties of the contact lens.

show abstract

Section: Lysozyme Adherence Studiesmentioning

confidence: 67%

In vitro and in vivo evaluation of brimonidine loaded silica nanoparticles-laden silicone contact lenses to manage glaucoma

2022

J Biomater Appl

View full text Add to dashboard Cite

show abstract

“…Ultimately, the developed PEGylated chitosan-coated SLNs improved the ocular bioavailability of ofloxacin by increasing the drug concentration in rabbits’ eyes two- to three-fold when compared to the plain drug [ 148 ]. The PEGylation approach was also adopted by Dang et al, who developed a PEGylated SLNs-laden contact lens, characterized by an enhanced latanoprost-loading capacity, smaller sizes (compared to non-PEGylated SLNs), and sustained drug release up to 96 h [ 149 ].…”

Section: Feasibility Of Lipid Nanoparticles In Ophthalmologymentioning

confidence: 99%

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Gugleva

Andonova

2023

Pharmaceuticals

View full text Add to dashboard Cite

Sufficient ocular bioavailability is often considered a challenge by the researchers, due to the complex structure of the eye and its protective physiological mechanisms. In addition, the low viscosity of the eye drops and the resulting short ocular residence time further contribute to the observed low drug concentration at the target site. Therefore, various drug delivery platforms are being developed to enhance ocular bioavailability, provide controlled and sustained drug release, reduce the number of applications, and maximize therapy outcomes. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) exhibit all these benefits, in addition to being biocompatible, biodegradable, and susceptible to sterilization and scale-up. Furthermore, their successive surface modification contributes to prolonged ocular residence time (by adding cationic compounds), enhanced penetration, and improved performance. The review highlights the salient characteristics of SLNs and NLCs concerning ocular drug delivery, and updates the research progress in this area.

show abstract

“…Recently, NPs of poly-ethyl-glycole (PEG) were used to engineer CLs with the aim of delivering latanoprost (LTP) in the posterior ocular segment and reducing IOP in glaucoma. The results demonstrated that CLs loaded with PEG-NPs compared to the non-loaded and traditional drug-impregnated lenses have a higher drug absorption capacity and a controlled release rate up to 120 and 96 h. Therefore, in conclusion, the authors assumed that these systems could represent excellent substitutes to the conventional drug delivery systems [ 91 ].…”

Section: Contact Lensesmentioning

confidence: 99%

Innovation in the Development of Synthetic and Natural Ocular Drug Delivery Systems for Eye Diseases Treatment: Focusing on Drug-Loaded Ocular Inserts, Contacts, and Intraocular Lenses

et al. 2023

View full text Add to dashboard Cite

Nowadays, ocular drug delivery still remains a challenge, since the conventional dosage forms used for anterior and posterior ocular disease treatments, such as topical, systemic, and intraocular administration methods, present important limitations mainly related to the anatomical complexity of the eye. In particular, the blood–ocular barrier along with the corneal barrier, ocular surface, and lacrimal fluid secretion reduce the availability of the administered active compounds and their efficacy. These limitations have increased the need to develop safe and effective ocular delivery systems able to sustain the drug release in the interested ocular segment over time. In the last few years, thanks to the innovations in the materials and technologies employed, different ocular drug delivery systems have been developed. Therefore, this review aims to summarize the synthetic and natural drug-loaded ocular inserts, contacts, and intraocular lenses that have been recently developed, emphasizing the characteristics that make them promising for future ocular clinical applications.

show abstract

Sustained latanoprost release from PEGylated solid lipid nanoparticle-laden soft contact lens to treat glaucoma

Cited by 39 publications

References 40 publications

In vitro and in vivo evaluation of brimonidine loaded silica nanoparticles-laden silicone contact lenses to manage glaucoma

In vitro and in vivo evaluation of brimonidine loaded silica nanoparticles-laden silicone contact lenses to manage glaucoma

Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms

Innovation in the Development of Synthetic and Natural Ocular Drug Delivery Systems for Eye Diseases Treatment: Focusing on Drug-Loaded Ocular Inserts, Contacts, and Intraocular Lenses

Contact Info

Product

Resources

About